Tesla, Bank OZK And 3 Stocks To Watch Heading Into Wednesday

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

  • Tesla, Inc. (NASAQ: TSLA) reported a sharp increase in China sales for the month of June. The company delivered 93,680 units of Giga Shanghai-made cars in June, according to data from the China Passenger Car Association, which represents a 18.72% increase from a year-ago and 20.57% growth from April’s sales. Data released by the Elon Musk-led company showed that it delivered 466,140 units globally in the quarter. Tesla shares jumped 6.9% to close at $279.82 on Monday, but lost 0.3% in the after-hours trading session.
  • Bank OZK (NASDAQ:OZK) increased its quarterly common stock dividend from $0.35 to $0.36 per share. Bank OZK shares declined 0.4% to $40.30 in the after-hours trading session.
  • Arrival (NASDAQ:ARVL) said on Monday that its proposed merger with special purpose acquisition company Kensington Capital Acquisition Corp V has been terminated. Arrival shares jumped 7.4% to $2.77 in after-hours trading.

Check out our premarket coverage here

  • Toyota Motor Corp (NYSE:TM) disclosed that it has achieved a technological breakthrough enabling a potential halving of the weight, size and cost of batteries, signaling a significant advancement for electric vehicles. Toyota Motor shares fell 0.1% to $160.32 in the after-hours trading session.
  • Evotec SE (NASDAQ:EVO) reported that its subsidiary, Just – Evotec Biologics, has been awarded a $74 million contract by the U.S. Department of Defense under Accelerated Antibodies Program. Evotec shares fell 0.1% to $11.08 in the after-hours trading session.

 

Read This Next: Top 5 Consumer Stocks That May Implode This Quarter

Total
0
Shares
Related Posts
Read More

MapKure, BeiGene And SpringWorks Present Clinical Data On BGB-3245, A Selective Next-Generation B-RAF Inhibitor, In Adult Patients With Advanced Or Refractory Solid Tumors At The American Association For Cancer Research Annual Meeting 2023

MapKure, LLC, BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)))), and SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), today announced that they will present updated clinical data from the Phase 1a/1b study of

BGNE